US · SPRO · BIOTECHNOLOGY
Spero Therapeutics, Inc. (SPRO) intrinsic value and stock valuation
$0.74as of 2026-11-21 · Mkt cap 72.96M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Spero Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values SPRO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SPRO’s statements →
Spero Therapeutics, Inc. Graham Number
Graham Number: $1.90d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2015–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Opus Genetics, Inc. (IRD) $3.99
- Corbus Pharmaceuticals Holdings, Inc. (CRBP) $2.06
- Acumen Pharmaceuticals, Inc. (ABOS) $0.19
- TuHURA Biosciences, Inc. (HURA) $1.25
- Seer, Inc. (SEER) $1.36
- Cognition Therapeutics, Inc. (CGTX) $0.58
- Seres Therapeutics, Inc. (MCRB) $1.24
- Inovio Pharmaceuticals, Inc. (INO) $1.76
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $59.6M | $48M | $103.8M | $48.6M | $3.07M |
| Operating income | -$-20K | -$-73.36M | $21.5M | -$-42.2M | -$-87.97M |
| Net income | $8.57M | -$-68.57M | $22.8M | -$-46.41M | -$-89.76M |
| EPSd | $145.2K | -$-1.27M | $430.5K | -$-1.23M | -$-2.9M |
| Operating cash flow | -$-12.62M | -$-23.44M | -$-32.99M | -$-7.73M | -$-64.35M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $64.4M |
| Free cash flow | -$-12.62M | -$-23.44M | -$-32.99M | -$-7.73M | -$-64.35M |
| Total assets | $68.9M | $110.5M | $182.4M | $124.8M | $171.1M |
| Total debt | $2.9M | $4.3M | $5.54M | $6.65M | $7.33M |
| Net debt | -$-37.37M | -$-48.59M | -$-70.79M | -$-102.46M | -$-105.25M |
| Total equity | $59M | $46.1M | $106.9M | $75.9M | $88.3M |
| Cash and short-term investments | $40.3M | $52.9M | $76.3M | $109.1M | $146.4M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $59.6M | $48M | $103.8M | $48.6M | $3.07M |
| Cost of revenue | $0.00 | $96.8M | $51.4M | $0.00 | $0.00 |
| Gross profit | $59.6M | -$-48.78M | $52.3M | $48.6M | $3.07M |
| Research and development expenses | $38.5M | $96.8M | $51.4M | $47.6M | $64.5M |
| Selling, general and administrative expenses | $21.2M | $23.7M | $25.6M | $36.5M | $41.7M |
| Other expenses | $0.00 | -$-95.88M | -$-46.13M | $6.7M | -$-15.19M |
| Operating expenses | $59.6M | $24.6M | $30.9M | $90.8M | $91M |
| Cost and expenses | $59.6M | $121.3M | $82.3M | $90.8M | $91M |
| Interest income | $2.51M | $4.74M | $3.94M | $1.11M | $350K |
| Interest expense | $0.00 | $0.00 | $0.00 | $2.6M | $1.94M |
| Depreciation and amortization | $0.00 | $0.00 | $370K | $870K | $650K |
| Ebitda | $8.83M | -$-72.48M | $27.2M | -$-42.94M | -$-87.17M |
| Operating income | -$-20K | -$-73.36M | $21.5M | -$-42.2M | -$-87.97M |
| Total other income/expenses, net | $8.86M | $4.79M | $3.92M | -$-4.22M | -$-1.78M |
| Income before tax | $8.83M | -$-68.57M | $25.4M | -$-46.41M | -$-89.76M |
| Income tax expense | $260K | $0.00 | $2.6M | $0.00 | $0.00 |
| Net income | $8.57M | -$-68.57M | $22.8M | -$-46.41M | -$-89.76M |
| Weighted average shares outstanding | $56M | $54M | $52.7M | $37.6M | $30.9M |
| Weighted average diluted shares outstanding | $59M | $54M | $53M | $37.6M | $30.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $40.3M | $52.9M | $76.3M | $109.1M | $146.4M |
| Net receivables | $25.4M | $52.5M | $50.7M | $1.08M | $2.64M |
| Inventory | $0.00 | $0.00 | $0.00 | -$-4.46M | $0.00 |
| Total current assets | $67.3M | $107.3M | $131.2M | $109.1M | $157.9M |
| Property, plant and equipment, net | $1.48M | $3.11M | $4.16M | $5.49M | $7.56M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $46.6M | $0.00 | $0.00 |
| Total non-current assets | $1.63M | $3.27M | $51.2M | $15.7M | $13.2M |
| Total assets | $68.9M | $110.5M | $182.4M | $124.8M | $171.1M |
| Accounts payable | $690K | $7.31M | $1.38M | $620K | $1.1M |
| Short-term debt | $1.96M | $1.75M | $1.72M | $1.69M | $1.36M |
| Deferred revenue | $260K | $22.1M | $27.1M | $10.4M | $1.86M |
| Total current liabilities | $8.87M | $49.1M | $37.2M | $21.7M | $18.7M |
| Long-term debt | $940K | $2.55M | $3.83M | $4.96M | $5.97M |
| Deferred revenue, non-current | $0.00 | $12.2M | $34.4M | $22.2M | $8.79M |
| Total non-current liabilities | $1.03M | $15.4M | $38.3M | $27.2M | $64.1M |
| Capital lease obligations | $940K | $2.55M | $3.83M | $4.96M | $7.33M |
| Total liabilities | $9.9M | $64.4M | $75.5M | $48.9M | $82.8M |
| Common stock | $60K | $60K | $50K | $50K | $30K |
| Retained earnings | -$-451.07M | -$-459.64M | -$-391.07M | -$-413.88M | -$-367.46M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | -$0.00 |
| Total equity | $59M | $46.1M | $106.9M | $75.9M | $88.3M |
| Total investments | $0.00 | $0.00 | $46.6M | $0.00 | $33.8M |
| Total debt | $2.9M | $4.3M | $5.54M | $6.65M | $7.33M |
| Net debt | -$-37.37M | -$-48.59M | -$-70.79M | -$-102.46M | -$-105.25M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $8.57M | -$-68.57M | $22.8M | -$-46.41M | -$-89.76M |
| Depreciation and amortization | $0.00 | $0.00 | $370K | $870K | $1.12M |
| Stock-based compensation | $4.33M | $7.79M | $7.93M | $9.12M | $9.43M |
| Change in working capital | -$-27.16M | $36.3M | -$-70.38M | $22.1M | $12.9M |
| Accounts receivable | $3.06M | -$-1.54M | -$-460K | $1.55M | $3.83M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-6.61M | $5.93M | $760K | -$-480K | -$-50K |
| Net cash provided by operating activities | -$-12.62M | -$-23.44M | -$-32.99M | -$-7.73M | -$-64.35M |
| Investments in property, plant and equipment | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $40K |
| Net cash used for investing activities | $0.00 | $0.00 | $0.00 | $33.8M | $7.67M |
| Common stock issued | $0.00 | $0.00 | $220K | $24.9M | $36.6M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $0.00 | $0.00 | $220K | -$-29.55M | $84.1M |
| Net change in cash | -$-12.62M | -$-23.44M | -$-32.77M | -$-3.48M | $27.4M |
| Cash at end of period | $40.3M | $52.9M | $76.3M | $109.1M | $112.6M |
| Operating cash flow | -$-12.62M | -$-23.44M | -$-32.99M | -$-7.73M | -$-64.35M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $64.4M |
| Free cash flow | -$-12.62M | -$-23.44M | -$-32.99M | -$-7.73M | -$-64.35M |
Line items
Line items
Line items
About Spero Therapeutics, Inc.
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.
- CEO
- Esther Rajavelu
- Employees
- 25
- Beta
- 1.49
Explore
Frequently asked questions
What is the intrinsic value of Spero Therapeutics, Inc. (SPRO)?
InvestorsCraft does not currently publish an intrinsic value for SPRO. How the IC value is calculated.
Is SPRO undervalued?
InvestorsCraft does not publish an undervaluation signal for SPRO at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.